Inside the New Whittle Laboratory in Cambridge, among the descendants of Frank Whittle's original turbojet prototypes, a quieter argument is unfolding about why Britain keeps inventing things it cannot keep. The lab's director talks of collapsing years of aerothermal engineering into weeks. His counterpart at the affiliated Bennett Innovation Lab talks of building a hardware equivalent to Silicon Valley's start-up machine. Both are chasing the same prize that has eluded Britain for decades: converting scientific advantage into companies that stay British long enough to matter.
A new book gathering contributions from entrepreneurs, investors and policymakers puts a name to this failure. It calls it the conversion gap, the distance between what Britain discovers and what Britain keeps. Arm, DeepMind and Oxford Ionics are cited as casualties, businesses with global ambition that found no domestic capital willing to back them at scale and so were sold abroad. One contributor, a venture capitalist who has backed eleven European unicorns, notes that every one of them eventually relocated to the United States. He calls this the single most damaging pattern in the continent's innovation economy.
Read that argument from inside the NHS and the parallel is not abstract. It is playing out now, in the argument over who builds the software that runs England's hospitals. The Federated Data Platform, awarded to a Palantir-led consortium in 2023 for up to £330 million, was meant to connect fragmented data across NHS trusts. It has instead become a case study in the same conversion failure the Whittle Lab is trying to solve, except in reverse. Rather than a British innovation being sold overseas, the NHS handed a foundational piece of its own data infrastructure to an overseas supplier by default, in the absence of a domestic alternative capable of delivering at the same scale.
The contract's structure now makes this legible. Its first term expires in March 2027, with the government due to decide whether to trigger an extension. Health minister Zubir Ahmed has told Parliament the arrangement could be reconsidered if another supplier can do the job better. That single sentence is the conversion gap in miniature. There is no queue of credible domestic challengers standing behind Palantir, ready to take on a national contract of that scale. NHS England's own data engineering capability, built up alongside the platform, is real but partial. A Solution Exchange has been created to draw in other vendors, but it has not yet produced the kind of scaled, investable British alternative that the Whittle Lab's founders are trying to engineer for aerospace.
One contributor to the innovation blueprint, who chaired the Vaccine Taskforce during the pandemic, describes three ingredients that made rapid domestic delivery possible then: mission-driven teams, early public money committed without waiting for perfect certainty, and government departments moving in parallel rather than in sequence. Almost none of that discipline is visible in how NHS England has approached data platform procurement over the past decade. A former Cabinet Office digital director recently described fifteen years of failure to establish common data standards across the NHS, a vacuum that made it easier for a single company to end up owning the taxonomy by default. That is not a story about one supplier's ethics. It is a story about a purchaser that never built the conditions for a market to exist.
Andy Burnham's incoming government inherits this decision at an awkward moment. The instinct so far has leaned toward devolution and redistribution rather than enterprise policy, and there is little sign that life sciences procurement features prominently in its early priorities. Yet the FDP's break clause offers a rare, concrete test of whether ministers intend to close conversion gaps or simply manage the next one. Extending the contract without a serious plan to cultivate domestic suppliers repeats the pattern the Whittle Lab was built to escape. Declining to extend without one ready to replace it risks disruption to systems trusts have only recently begun to use.
Britain now has a fluent explanation for why its innovation economy leaks value abroad. Whether that explanation reaches as far as NHS procurement policy will become clear well before the decade is out.
